GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

trastuzumab   Click here for help

GtoPdb Ligand ID: 5082

Synonyms: D5v8 | Herceptin® | R-597
Approved drug
trastuzumab is an approved drug (FDA (1998), EMA (2000))
Compound class: Antibody
Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyApprovalsIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon India, FDA 2017, EMA 2018 (Ogivri)Breast cancer
trastuzumab-pkrb; CT-P6Herzuma; CredimaCelltrionS. Korea, EMA & FDA 2018Breast cancer
trastuzumab-dttb; SB3OntruzantSamsung BioepisEMA 2017, FDA 2019All approved indications of the reference product
trastuzumab-beta; trastuzumab-anns; ABP-980 [3]KanjintiAmgen/AllerganEMA 2018, FDA 2019All approved indications of the reference product
trastuzumab-qyyp; PF-05280014TrazimeraPfizerFDA 2019All approved indications of the reference product
trastuzumab-strf; HLX02Zercepac; HercessiShanghai Henlius Biotech; Accord HealthcareEMA 2020, FDA 2024EMA approved to treat HER2 positive metastatic breast cancer; FDA approval indicated for breast cancer plus HER2-overexpressing gastric or gastroesophageal junction adenocarcinomas
trastuzumab; EG12014HerwendaSandoz EMA 2023Early breast cancer and metastatic gastric cancer
biosimilar trastuzumabDazublysCuraTeQ Biologics EMA & UK MHRA 2025HER2-positive metastatic or early stage breast cancer
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

Bioactivity Comments
The use of anti-HER2 monoclonals is covered by patent WO1989006692, in which the clone that produced trastuzumab is 4D5 [1]. Efficacy of the resultant monoclonals was assessed in vitro (for example ELISA for antigen binding and in vitro cellular assays for anti-tumour activity) but no affinity value for the interaction between the antibody and its antigen are provided in the patent.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
erb-b2 receptor tyrosine kinase 2 Primary target of this compound Hs Antibody Inhibition - - -
⤷
Ligand mentioned in the following text fields
Type I RTKs: ErbB (epidermal growth factor) receptor family comments